PT1183050E - Processo para a produção de uma preparação farmacêutica injectável - Google Patents

Processo para a produção de uma preparação farmacêutica injectável

Info

Publication number
PT1183050E
PT1183050E PT00945721T PT00945721T PT1183050E PT 1183050 E PT1183050 E PT 1183050E PT 00945721 T PT00945721 T PT 00945721T PT 00945721 T PT00945721 T PT 00945721T PT 1183050 E PT1183050 E PT 1183050E
Authority
PT
Portugal
Prior art keywords
drug
spacer
producing
medicament preparation
injectable medicament
Prior art date
Application number
PT00945721T
Other languages
English (en)
Inventor
Felix Kratz
Original Assignee
Ktb Tumorforschungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910588&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1183050(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ktb Tumorforschungs Gmbh filed Critical Ktb Tumorforschungs Gmbh
Publication of PT1183050E publication Critical patent/PT1183050E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT00945721T 1999-06-09 2000-06-07 Processo para a produção de uma preparação farmacêutica injectável PT1183050E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19926154A DE19926154A1 (de) 1999-06-09 1999-06-09 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung

Publications (1)

Publication Number Publication Date
PT1183050E true PT1183050E (pt) 2007-01-31

Family

ID=7910588

Family Applications (3)

Application Number Title Priority Date Filing Date
PT00945721T PT1183050E (pt) 1999-06-09 2000-06-07 Processo para a produção de uma preparação farmacêutica injectável
PT101838704T PT2347770T (pt) 1999-06-09 2000-06-07 Processo de produção de uma preparação farmacêutica injetável
PT06012171T PT1704864E (pt) 1999-06-09 2000-06-07 Preparação farmacêutica injectável que consiste num agente citostático e num grupo maleinimida ligados por um espaçador

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT101838704T PT2347770T (pt) 1999-06-09 2000-06-07 Processo de produção de uma preparação farmacêutica injetável
PT06012171T PT1704864E (pt) 1999-06-09 2000-06-07 Preparação farmacêutica injectável que consiste num agente citostático e num grupo maleinimida ligados por um espaçador

Country Status (13)

Country Link
US (5) US7387771B1 (pt)
EP (3) EP2347770B2 (pt)
JP (5) JP5517384B2 (pt)
AT (1) ATE339225T1 (pt)
AU (1) AU779697B2 (pt)
CA (1) CA2374964C (pt)
CY (2) CY1105701T1 (pt)
DE (2) DE19926154A1 (pt)
DK (3) DK2347770T4 (pt)
ES (3) ES2385230T3 (pt)
PT (3) PT1183050E (pt)
SI (1) SI1704864T1 (pt)
WO (1) WO2000076551A2 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE443714T1 (de) 1999-05-17 2009-10-15 Conjuchem Biotechnologies Inc Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE252601T1 (de) 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP1889639A3 (en) * 1999-09-07 2008-04-09 ConjuChem Biotechnologies Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
JP2003508502A (ja) * 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド 長期存続抗腫瘍剤の産生のための方法および組成物
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US6961567B1 (en) * 2000-12-07 2005-11-01 Palm, Inc. Generic activation and registration framework for wireless devices
US7555571B1 (en) * 2001-01-05 2009-06-30 Palm, Inc. Activation of mobile computing device on a cellular network
AU2002233082B2 (en) 2001-02-02 2005-11-10 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US8812398B2 (en) * 2001-05-08 2014-08-19 Qualcomm Incorporated Key for a wireless-enabled device
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
WO2004054622A1 (en) 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
DE10310082A1 (de) 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
GB0321613D0 (en) * 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
DE102005002991A1 (de) * 2005-01-21 2006-07-27 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Gyrasehemmern
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
DE102006024528A1 (de) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg Neue, an der Tumorphysiologie orientierte Formulierung eines Zytostatikums, insbesondere von cis-Platin
DE102007002726A1 (de) * 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
ES2704199T3 (es) 2007-02-16 2019-03-14 Vergell Medical S A Profármacos de doble acción
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2289558A1 (en) * 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
EP2382993A1 (en) 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
HRP20220399T1 (hr) 2012-12-13 2022-05-13 Immunomedics, Inc. Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
EP2931042B1 (en) 2012-12-13 2021-04-28 CytRx Corporation Anthracycline formulations
JP6482471B2 (ja) 2012-12-21 2019-03-13 バイオアライアンス コマンディテール フェンノートシャップ 親水性の自壊性リンカー及びそのコンジュゲート
JP2016521705A (ja) 2013-06-05 2016-07-25 サイトレックス コーポレイション がんを処置するための細胞傷害剤
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
WO2016080626A2 (en) 2014-11-20 2016-05-26 Pharosgen Prodrugs activated by caspase
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
ES2909486T3 (es) * 2015-06-19 2022-05-06 Centurion Biopharma Corp Sistemas de administración para liberación controlada de fármaco
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017097986A1 (en) 2015-12-09 2017-06-15 Medizinische Universität Wien Monomaleimide-functionalized platinum compounds for cancer therapy
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017147240A1 (en) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Hsp90 targeted conjugates and particles and formulations thereof
WO2017189279A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2018183041A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
EP3668538A4 (en) 2017-08-15 2021-06-16 NantCell, Inc. COMBINATIONS OF CÉTUXIMAB AND NATURAL KILLER CELLS WITH HIGH AFFINITY AND RELATED METHODS
JP2021014409A (ja) * 2017-11-21 2021-02-12 京都薬品工業株式会社 タンパク質結合性薬物
KR20200117988A (ko) * 2017-11-30 2020-10-14 센추리온 바이오파마 코포레이션 메이탄시노이드계 약물 전달 시스템
CA3083983A1 (en) 2017-11-30 2019-06-06 Centurion Biopharma Corporation Albumin-binding prodrugs of auristatin e derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251445A (en) 1978-03-24 1981-02-17 Weltman Joel K N-succinimidyl haloacetyl aminobenzoates as coupling agents
DE3060377D1 (en) 1979-08-29 1982-07-01 Nihon Mediphysics Co Ltd 2-oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
EP0493745A1 (en) 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1996008263A1 (en) 1994-09-13 1996-03-21 Theratech, Inc. Intracellular delivery of chemical agents to a specific cell type
IT1282625B1 (it) * 1996-02-14 1998-03-31 Zambon Spa Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5879897A (en) * 1996-09-23 1999-03-09 Wake Forest University Methods and compositions for the diagnosis of extraesophageal gastric reflux
NZ337924A (en) * 1997-02-20 2002-09-27 Klaus Kimmeldirk Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
DE19923168A1 (de) * 1999-05-20 2000-11-23 Roche Diagnostics Gmbh Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20060233701A1 (en) 2005-03-30 2006-10-19 Thomas Parias Method and apparatus to improve the industrial production of hydrogen-carbon monoxide

Also Published As

Publication number Publication date
ES2623017T5 (es) 2020-04-07
ATE339225T1 (de) 2006-10-15
CA2374964A1 (en) 2000-12-21
WO2000076551A2 (de) 2000-12-21
EP1704864B9 (de) 2012-09-19
JP2018035191A (ja) 2018-03-08
US20100215574A1 (en) 2010-08-26
JP2011173913A (ja) 2011-09-08
DK1704864T3 (da) 2012-09-03
US8846602B2 (en) 2014-09-30
WO2000076551A3 (de) 2001-08-16
US20150196573A1 (en) 2015-07-16
DK2347770T4 (da) 2020-02-03
JP6290166B2 (ja) 2018-03-07
EP1704864A3 (de) 2007-01-10
ES2269160T3 (es) 2007-04-01
DK1183050T3 (da) 2007-01-02
EP2347770A2 (de) 2011-07-27
EP2347770B2 (de) 2019-10-23
EP1704864B1 (de) 2012-05-23
EP2347770A3 (de) 2011-11-09
JP2016047847A (ja) 2016-04-07
ES2385230T3 (es) 2012-07-19
ES2623017T3 (es) 2017-07-10
DE50013468D1 (de) 2006-10-26
US7387771B1 (en) 2008-06-17
JP6573947B2 (ja) 2019-09-11
DE19926154A1 (de) 2000-12-14
CY1105701T1 (el) 2010-12-22
JP5517384B2 (ja) 2014-06-11
CA2374964C (en) 2012-05-22
US8153581B2 (en) 2012-04-10
EP1183050A2 (de) 2002-03-06
US20120195832A1 (en) 2012-08-02
EP2347770B1 (de) 2017-03-08
DK2347770T3 (en) 2017-07-03
US20060233707A1 (en) 2006-10-19
PT1704864E (pt) 2012-07-02
JP5871483B2 (ja) 2016-03-01
CY1113370T1 (el) 2016-06-22
PT2347770T (pt) 2017-06-20
EP1183050B1 (de) 2006-09-13
SI1704864T1 (sl) 2012-09-28
JP2003501486A (ja) 2003-01-14
JP2014055192A (ja) 2014-03-27
AU779697B2 (en) 2005-02-10
AU5970900A (en) 2001-01-02
EP1704864A2 (de) 2006-09-27

Similar Documents

Publication Publication Date Title
PT1183050E (pt) Processo para a produção de uma preparação farmacêutica injectável
PT781778E (pt) Novos pro-farmacos de paclitaxel metodo para a sua preparacao bem como a sua utilizacao em quimioterapia selectiva
WO2002101412A3 (en) Spray freeze-dried compositions
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
CA2193129A1 (en) Transdermal drug delivery system
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
WO2001037896A3 (en) Methods and compositions for administration of therapeutic reagents
MXPA03000820A (es) Compuestos terapeuticos de polianhidrido para suministro de farmacos.
IL160085A (en) Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
WO2007098479A3 (en) Localized insulin delivery for bone healing
ES8506446A1 (es) Procedimiento para preparar formas galenicas que contienen sulfonilureas y-0 derivados del acido benzoico.
IL145755A0 (en) Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
GR1002847B (el) Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
ATE289801T1 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
WO2001000566A3 (en) Substituted phenoxyacetic acids
UY25800A1 (es) Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.
BR9609051A (pt) Composição farmacêutica preparada por adição de um veículo flavorizante a um medicamento
WO2004058143A3 (en) High specificity anticancer pharmacological drug system, drug synthesis, and drug development process
DE60008293D1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung
WO1998011919A3 (en) Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof
JP2002529515A5 (pt)
EP1288311A3 (en) Method for testing small pharmaceutically active molecules in the activation of Pax4 and production of insulin producing beta-cells